Mulnitorsen is under clinical development by Andes Biotechnologies and currently in Phase I for Gallbladder Cancer. According to GlobalData, Phase I drugs for Gallbladder Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Mulnitorsen LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mulnitorsen overview
Andes-1537 is under development for the treatment of relapsed and refractory solid tumors including bladder cancer, pancreatic cancer, cholangiocarcinoma, colorectal cancer, gallbladder adenocarcinoma, cervical cancer, gastric adenocarcinoma. It is administered by subcutaneous injection. The drug candidate is an antisense oligonucleotide.
It was under development for renal cell carcinoma.
Andes Biotechnologies overview
Andes Biotechnologies is a biotechnology company. The company provides nucleic acid-based drug discovery and development company focused on solid tumor cancers. It is headquartered in Santiago, Region Metropolitana, Chile.
For a complete picture of Mulnitorsen’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
